A novel role for peptidylarginine deiminases in microvesicle release reveals therapeutic potential of PAD inhibition in sensitizing prostate cancer cells to chemotherapy
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Introduction: Protein deimination, defined as the post‐translational conversion of protein‐bound arginine to citrulline, is carried out by a family of 5 calcium‐dependent enzymes, the peptidylarginine deiminases (PADs) and has been linked to various cancers. Cellular microvesicle (MV) release, which is involved in cancer progression, and deimination have not been associated before. We hypothesize that elevated PAD expression, observed in cancers, causes increased MV release in cancer cells and contributes to cancer progression. Background: We have previously reported that inhibition of MV release sensitizes cancer cells to chemotherapeutic drugs. PAD2 and PAD4, the isozymes expressed in patients with malignant tumours, can be inhibited with the pan‐PAD‐inhibitor chloramidine (Cl‐am). We sought to investigate whether Cl‐am can inhibit MV release and whether this pathway could be utilized to further increase the sensitivity of cancer cells to drug‐directed treatment. Methods: Prostate cancer cells (PC3) were induced to release high levels of MVs upon BzATP stimulation of P2X 7 receptors. Western blotting with the pan‐protein deimination antibody F95 was used to detect a range of deiminated proteins in cells stimulated to microvesiculate. Changes in deiminated proteins during microvesiculation were revealed by immunoprecipitation and immunoblotting, and mass spectrometry identified deiminated target proteins with putative roles in microvesiculation. Conclusion: We report for the first time a novel function of PADs in the biogenesis of MVs in cancer cells. Our results reveal that during the stimulation of prostate cancer cells (PC3) to microvesiculate, PAD2 and PAD4 expression levels and the deimination of cytoskeletal actin are increased. Pharmacological inhibition of PAD enzyme activity using Cl‐am significantly reduced MV release and abrogated the deimination of cytoskeletal actin. We demonstrated that combined Cl‐am and methotrexate (MTX) treatment of prostate cancer cells increased the cytotoxic effect of MTX synergistically. Refined PAD inhibitors may form part of a novel combination therapy in cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Extracellular vesicles: Exosomes, microvesicles, and friends
Raposo, G., & Stoorvogel, W. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201211138 · Cited by 8,099 · cited 1×
“Since the process of multivesicular body recruitment to the plasma membrane to release exosomal cargo likely involves actin and microtubular elements of the cytoskeleton (76), it may well be that PADs and deimination of actin are also involved in exosomal release.”
BackgroundIshigami, A., Ohsawa, T., Hiratsuka, M., Taguchi, H., Kobayashi, S., Saito, Y., Murayama, S., Asaga, H., Toda, T., Kimura, N., et al. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20431 · Cited by 297
Cited by
Therapeutically harnessing extracellular vesicles
Cheng, L., & Hill, A. F. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00410-w · Cited by 737
Inhibiting extracellular vesicles formation and release: a review of EV inhibitors
Catalano, M., & O'Driscoll, L. (2020) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2019.1703244 · Cited by 658
Maacha, S., Bhat, A. A., Jimenez, L., Raza, A., Haris, M., Uddin, S., & Grivel, J.-C. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0965-7 · Cited by 572
Mauracher, L. ‐., Posch, F., Martinod, K., Grilz, E., Däullary, T., Hell, L., Brostjan, C., Zielinski, C., Ay, C., Wagner, D. D., et al. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13951 · Cited by 303
De Sousa, K. P., Rossi, I., Abdullahi, M., Ramirez, M. I., Stratton, D., & Inal, J. M. (2023) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1835 · Cited by 300
Self-citation
Metadata
- Authors
- Kholia, S., Jorfi, S., Thompson, P. R., Causey, C. P., Nicholas, A. P., Inal, J. M., & Lange, S.
- Venue
- Journal of Extracellular Vesicles
- Publisher
- Wiley
- Published
- 2015-01
- Volume
- 4
- Issue
- 1
- Pages
- 26192-26192
- ISSN
- 2001-3078 (ISSN-L)
- OpenAlex
- W2133494286
- Cited by
- 122
- References
- 2
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.